Full-Time

Quality Operations Manager

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$120k - $144k/yr

Rensselaer, NY, USA

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
FDA Regulations
Quality Assurance (QA)
Microbiology

Get referred to Curia

See people who can refer or advise you

Requirements
  • A Bachelor’s Degree in Microbiology, Chemistry, or a related field, plus 8–10 years of related industrial Good Manufacturing Practice experience in an FDA-regulated pharmaceutical environment, including 2 years of supervisory experience; or a Master’s Degree in Microbiology, Chemistry, or a related field, plus at least 3 years of related industrial Good Manufacturing Practice experience in an FDA-regulated pharmaceutical environment, including 2 years of supervisory experience.
  • Strong background in deviations, batch review, and disposition.
  • Must pass a background check.
  • Must pass a drug screen.
  • May be required to pass Occupational Health Screening.
Responsibilities
  • Assist the Site Quality Head with developing, implementing, and enforcing the quality assurance program.
  • Develop and/or review standards, policies, and procedures for functions and departments involved in or related to the production and testing of materials.
  • Oversee a robust batch disposition program, including holistic batch record review training for Operations and Quality.
  • Ensure data integrity principles are understood and implemented consistently throughout the site.
  • Ensure operational deviations are investigated, product impact is determined, and findings are documented within the Quality System before disposition.
  • Oversee the site walkthrough program, identify key improvement themes, and drive improvement.
  • Develop and maintain a real-time batch record review program.
  • Ensure a robust cleaning and sanitization program is in place.
  • Develop and maintain a disposition review process involving key stakeholders, and drive accountability for right-first-time and yield-to-release metrics.
  • Review and approve major deviations initiated for manufacturing activities.
  • Partner with site stakeholders to achieve and maintain operational excellence, site quality compliance, and a strong site-wide quality culture while achieving site business goals.
  • Lead and support site-wide current Good Manufacturing Practice training activities.
  • Communicate with internal and external customers to ensure Curia values and business goals are achieved.
  • Ensure a robust line-clearance process is in place and followed.
  • Interface with customers regarding batch record queries, manufacturing deviations, and yield-to-release data.
  • Ensure manufacturing quality issues are promptly escalated through the NTM process.
  • Develop and maintain leading-indicator metrics for quality oversight on the manufacturing floor.
Desired Qualifications
  • Advanced degree in a related field.
  • Prior work experience in a contract manufacturing organization.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.